Generic Drugs/Biosimilars

Oct 04, 2016
By Pharmaceutical Technology Editors
Xellia added laboratory space and personnel in Zagreb, Croatia to work on anti-infective products that combat the antimicrobial resistance problem.
Sep 30, 2016
By Pharmaceutical Technology Editors
Ravi Limaye gives an overview of the biosimilar industry and projects for 2020.
Sep 29, 2016
By Pharmaceutical Technology Editors
Containing costs and improving compliance will be crucial to ensuring the growth of generic pharmaceuticals in the future, says Dilip Shah, CEO of Vision Consulting Group, in CPhI’s 2016 Annual Report, which will be formally issued at CPhI 2016 in Barcelona.
Sep 29, 2016
By Pharmaceutical Technology Editors
Alan Sheppard, Principal, Global Generics at IMS Health and CPhI expert panel member, discusses generic medicine opportunities in the 2016 CPhI Annual Industry Report.
Sep 26, 2016
By Pharmaceutical Technology Editors
The agency approves Amjevita (adalimumab-atto) for the treatment of inflammatory diseases.
Sep 22, 2016
By Pharmaceutical Technology Editors
The agency published the guidance to help generic-drug facilities comply with the GDUFA self-identification requirement.
Sep 12, 2016
Concerns have emerged that continued growth in the biosimilars market could be limited by mounting pressure to push down on prescription drug outlays.
Sep 09, 2016
If FDA’s proposed generic-drug labeling rule is passed in 2017, generic drug companies would need documented processes for safety tracking and label updates.
Sep 02, 2016
Pharmaceutical Technology
Companies may potentially accelerate the approval of generic drugs by avoiding deficiencies in ANDA submissions.
Sep 01, 2016
By Pharmaceutical Technology Editors
GPhA and PBOA commend agreement to reauthorize Generic Drug User Fee Amendments.
native1_300x100
lorem ipsum